PERSON – Page 14

RyCarma Therapeutics Unveils New Leadership and Company Name, Expands Focus on Heart Failure Treatment

3 months ago talkbio0Tagged ARMGO, biotech company, Cardiovascular Diseases, Changing, Heart failure, Leadership, Pharma, Rycals, RyCarma, skeletal muscle diseases

RyCarma Therapeutics, ARMGO Pharma, ryanodine receptor, Rycals, heart failure, cardiovascular diseases, skeletal muscle diseases, biotech company, new leadership, company name change.

DEA Unveils Special Registration Framework for Telehealth Prescribing of Controlled Substances

3 months ago talkbio0Tagged controlled substance, DEA Special Registration, Flexibilities, Prescribed, regulatory, Telemedicine

DEA Special Registration, Telehealth Prescribing, Controlled Substances, Telemedicine Flexibilities, Ryan Haight Act, Telemedicine Regulations

First Lady Jill Biden Continues to Champion Women’s Health Research Beyond White House Tenure

3 months ago talkbio0Tagged ARPA-H, Gender, Health care facility, health research, Healthcare Disparities, Jill, White House Initiative, women 's

Jill Biden, women’s health research, White House Initiative, ARPA-H, healthcare disparities, gender gap in healthcare

Tune Therapeutics Secures $175M in Series B Funding to Advance Epigenome Editing Programs

3 months ago talkbio0Tagged biotech, Epigenome, gene therapy, Hepatitis B treatment, Investments, Series B, Tune

Epigenome editing, Tune Therapeutics, Series B funding, Hepatitis B treatment, Gene therapy, Biotech investment

RegenXBio Secures $110M Upfront in Strategic Partnership with Nippon Shinyaku for Hunter Syndrome Gene Therapy

3 months ago talkbio0Tagged Gene, gene therapy, Mucopolysaccharidosis II, Nippon, Regenxbio, RGX-111, RGX-121, Shinyaku, strategic partnership

RegenXBio, Hunter syndrome, Gene therapy, Nippon Shinyaku, Strategic partnership, Rare metabolic disorder, Mucopolysaccharidosis type II (MPS II), RGX-121, RGX-111

BridgeBio Pharma Reports Strong Commercial Progress and Pipeline Updates for 2025

3 months ago talkbio0Tagged 2025, Attruby, BridgeBio Pharma, Clinical Trials, commercial, FORTIFY, Hereditary Diseases, milestones, Phase 3, Propel, status - In progress

BridgeBio Pharma, Attruby, commercial progress, pipeline updates, 2025 milestones, rare genetic diseases, Phase 3 clinical trials, FORTIFY, CALIBRATE, PROPEL 3.